View in EDS HTML Full Text PDF Full Text

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.

Saved in:
Bibliographic Details
Title: Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
Authors: Conaghan, Philip1 (AUTHOR), Cohen, Stanley2 (AUTHOR), Burmester, Gerd3 (AUTHOR), Mysler, Eduardo4 (AUTHOR), Nash, Peter5 (AUTHOR), Tanaka, Yoshiya6 (AUTHOR), Rigby, William7 (AUTHOR), Patel, Jayeshkumar8 (AUTHOR) jayesh.patel@abbvie.com, Shaw, Tim9 (AUTHOR), Betts, Keith A.10 (AUTHOR), Patel, Pankaj8 (AUTHOR), Liu, Jianzhong8 (AUTHOR), Sun, Rochelle11 (AUTHOR), Fleischmann, Roy12 (AUTHOR)
Source: Rheumatology & Therapy. Feb2022, Vol. 9 Issue 1, p191-206. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21986576
DOI:10.1007/s40744-021-00399-5